LNTH vs MNPR
LNTH: Lantheus is a specialist in diagnostic imaging agents and radiopharmaceuticals that help clinicians visualize cardiovascular conditions and oncological disease states. MNPR: Monopar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of oncology therapeutics, including novel radiopharmaceutical agents.
Side-by-side fundamentals
| Metric | LNTH | MNPR | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $100.12 | $83.98 | |
| Market cap | $6.5B | $564M | |
| P/E as of 2026-10-08 | 24.22 | n/a | |
| Net margin FY2025, SEC XBRL | +15.2% | n/a | |
| Gross margin FY2025, SEC XBRL | +61.1% | n/a | |
| Operating margin FY2025, SEC XBRL | +20.2% | n/a | |
| ROE FY2025, SEC XBRL | +21.4% | -10.0% | LNTH higher |
| ROA FY2025, SEC XBRL | +10.5% | -9.7% | LNTH higher |
| Debt / equity as of 2026-09-03 | 0.44 | 0.00 | MNPR lower |
| Revenue growth (YoY) as of 2026-09-03 | +2.4% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +18.1% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.38 | 1.53 | |
| 1-year return as of 2026-10-08 close | +87.0% | -14.8% | LNTH higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.